{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:54:03Z","timestamp":1765886043286,"version":"3.48.0"},"reference-count":42,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,12,21]]},"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>New cholesterol treatment guidelines from American College of Cardiology\/American Heart Association recommend statin treatment for more of US population to prevent atherosclerotic cardiovascular disease (ASCVD). It is important to assess how new guidelines may affect population-level health. This study assessed the impact of statin use for primary prevention of ASCVD under the new guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from 2010 US Multiple Cause Mortality, Third National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File (1988\u20132006, n=8941) and NHANES 2005\u20132010 (n=3178) participants 40\u201375\u2005years of age for the present study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 33.0 million adults meeting new guidelines for primary prevention of ASCVD, 8.8 million were taking statins; 24.2 million, including 7.7 million with diabetes, are eligible for statin treatment. If all those with diabetes used a statin, 2514 (95% CI 592 to 4142) predicted ASCVD deaths would be prevented annually with 482 (0 to 2239) predicted annual additional cases of myopathy based on randomised clinical trials (RCTs), and 11\u2005801 (9251 to 14\u2005916) using population-based study. Among 16.5 million without diabetes, 5425 (1276 to 8935) ASCVD deaths would be prevented annually with 16\u2005406 (4922 to 26\u2005250) predicted annual additional cases of diabetes and between 1030 (0 to 4791) and 24\u2005302 (19\u2005363 to 30\u2005292) additional cases of myopathy based on RCTs and population-based study. Assuming 80% eligible population take statins with 80% medication adherence, among those without diabetes, the corresponding numbers were 3472 (817 to 5718) deaths, 10\u2005500 (3150 to 16\u2005800) diabetes, 660 (0 to 3066) myopathy (RCTs), and 15\u2005554 (12\u2005392 to 19\u2005387) myopathy (population-based). The estimated total annual cost of statins use ranged from US$1.65 to US$6.5 billion if 100% of eligible population take statins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This population-based modelling study focused on impact of statin use on ASCVD mortality. Under the new guidelines, if all those eligible for primary prevention of ASCVD take statins, up to 12.6% of annual ASCVD deaths might be prevented, though additional cases of diabetes and myopathy likely occur.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Disclaimer:<\/jats:title>\n                    <jats:p>The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-011684","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T21:11:22Z","timestamp":1485292282000},"page":"e011684","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study"],"prefix":"10.1136","volume":"7","author":[{"given":"Quanhe","family":"Yang","sequence":"first","affiliation":[{"name":"Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathleen","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Merritt","sequence":"additional","affiliation":[{"name":"Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Bowman","sequence":"additional","affiliation":[{"name":"Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary G","family":"George","sequence":"additional","affiliation":[{"name":"Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W Dana","family":"Flanders","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"2025121513423678000_7.1.e011684.1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"2025121513423678000_7.1.e011684.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315665"},{"key":"2025121513423678000_7.1.e011684.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62388-0"},{"key":"2025121513423678000_7.1.e011684.4","doi-asserted-by":"crossref","unstructured":"Taylor F , Huffman MD , Macedo AF , et al . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):CD004816.doi:10.1093\/eurheartj\/ehr158","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"2025121513423678000_7.1.e011684.5","doi-asserted-by":"publisher","DOI":"10.1177\/2047487314525531"},{"key":"2025121513423678000_7.1.e011684.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2197"},{"key":"2025121513423678000_7.1.e011684.7","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"2025121513423678000_7.1.e011684.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"2025121513423678000_7.1.e011684.9","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-51"},{"key":"2025121513423678000_7.1.e011684.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2610"},{"key":"2025121513423678000_7.1.e011684.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.000071"},{"key":"2025121513423678000_7.1.e011684.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.860"},{"key":"2025121513423678000_7.1.e011684.13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7326\/0003-4819-159-1-201307020-00022","article-title":"Discontinuation of statins in routine care settings","volume":"159","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025121513423678000_7.1.e011684.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3528-5"},{"key":"2025121513423678000_7.1.e011684.15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-85"},{"key":"2025121513423678000_7.1.e011684.16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2013.80-c2","article-title":"Statins for primary prevention: problems with cardiovascular-risk estimation?","volume":"10","author":"Reiner","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2025121513423678000_7.1.e011684.17","unstructured":"Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Plan, and Operation of the Third National Health and Nutrition Examination Survey (NHANES III, 1988\u201394): Reference Manuals and Reports. Weighting and Estimation Methodology Report. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1998."},{"key":"2025121513423678000_7.1.e011684.18","unstructured":"National Center for Health Statistics (CDC) NCfHSN. National Health and Nutrition Examination Survey Questionnaires, Datasets, and Related Documentation. http:\/\/wwwcdcgov\/nchs\/nhanes\/nhanes_questionnaireshtm (accessed Jan 2014)."},{"key":"2025121513423678000_7.1.e011684.19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","article-title":"Enzymatic determination of total serum cholesterol","volume":"20","author":"Allain","year":"1974","journal-title":"Clin Chem"},{"key":"2025121513423678000_7.1.e011684.20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/clinchem\/41.5.717","article-title":"Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin","volume":"41","author":"Sugiuchi","year":"1995","journal-title":"Clin Chem"},{"key":"2025121513423678000_7.1.e011684.21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2025121513423678000_7.1.e011684.22","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (CDC). National Center for Health Statistics. National Health and Nutrition Examination Survey: prescription medications\u2014drug information (RXQ_DRUG). http:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/1999-2000\/RXQ_DRUG.htm (accessed May 2015).doi:10.1093\/eurheartj\/ehr158","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"2025121513423678000_7.1.e011684.23","unstructured":"CDC WONDER. Multiple cause of death data. Centers for Disease Control and Prevention. http:\/\/www.cdc.gov\/minorityhealth (accessed 11 Nov 2014)."},{"key":"2025121513423678000_7.1.e011684.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000350"},{"key":"2025121513423678000_7.1.e011684.25","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0126"},{"key":"2025121513423678000_7.1.e011684.26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"2025121513423678000_7.1.e011684.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"2025121513423678000_7.1.e011684.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu107"},{"key":"2025121513423678000_7.1.e011684.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31828124ad"},{"key":"2025121513423678000_7.1.e011684.30","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437740.48606.d1"},{"key":"2025121513423678000_7.1.e011684.31","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.22.2657"},{"key":"2025121513423678000_7.1.e011684.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.21.2012"},{"key":"2025121513423678000_7.1.e011684.33","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000435173.25936.e1"},{"key":"2025121513423678000_7.1.e011684.34","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq165"},{"key":"2025121513423678000_7.1.e011684.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"},{"key":"2025121513423678000_7.1.e011684.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6822"},{"key":"2025121513423678000_7.1.e011684.37","doi-asserted-by":"publisher","DOI":"10.2174\/1381612820666141013134447"},{"key":"2025121513423678000_7.1.e011684.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"2025121513423678000_7.1.e011684.39","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.121"},{"key":"2025121513423678000_7.1.e011684.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004"},{"key":"2025121513423678000_7.1.e011684.41","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-12-200906160-00009"},{"key":"2025121513423678000_7.1.e011684.42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i493"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-011684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:42:42Z","timestamp":1765834962000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-011684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,24]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/bmjopen-2016-011684"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-011684","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}